22 March 2024

Vator Securities advises Magle Chemoswed Holding in connection with its public offer to the shareholders of Amniotics

About Magle Chemoswed Holding 

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products.

The case

  • Amniotics is a clinical-stage biotech company developing innovative therapies based on amniotic fluid-derived mesenchymal stem cells. The company develops advanced therapy medicinal products (ATMPs) to treat diseases and injuries where effective treatments are currently lacking. Amniotics has an established GMP facility, approved and licensed by the Swedish Medical Products Agency. In parallel with its proprietary developing projects, the company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies. Amniotics is headquartered in Lund, Sweden. 
  • Through the proposed acquisition, Magle Group will take over Aminotics’ cGMP-licensed ATMP facility, thereby ensuring that Nordic research-based companies will have access to development and manufacturing support in this rapidly growing area of biotechnology. Further, the integration of Amniotics’ capabilities and knowledge with Magle Group’s groundbreaking DSM (Degradable Starch Microspheres) technology allows opportunities to broaden the DSM-based product portfolio. 
  • Magle Group remains committed to Amniotics’ ongoing project and clinical activities, based on the potential to provide long-term benefits to patients. Magle Group does not currently foresee any material changes to Amniotics’ operations, including operational sites, its management or employees or their terms of employment. However, Magle Group expects the business combination to offer synergies in the long-term perspective. 

Website: https://maglegroup.com/